API | faropenem medoxomil

faropenem medoxomil (Fropenem) Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase. It is available for oral use. ^Wikipedia

Chemistry

SMILES: C[C@@H](O)[C@@H]1[C@H]2SC(=C(N2C1=O)C(=O)O)[C@H]3CCCO3
InChIKey: HGGAKXAHAYOLDJ-FHZUQPTBSA-N
Mol. Mass: 285.32
ALogP: 0.37 Partition coefficient
ChEMBL Molecules:

faropenem

faropenem medoxomil

faropenem sodium

More Chemistry

Pharmacology

Mechanism of Action:
- Cell division protein FtsI (Peptidoglycan synthetase) (Staphylococcus aureus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

(5r,6s)-6-(r)-1-hydroxyethyl-7-oxo-3-(r)-2-tetrahydrofuryl-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate | a0026 | bay566854 | bay 566854 | bay 56-6854 | bay-566854 | bay-56-6854 | bay56-6854 | faropenem | faropenem daloxate | faropenem medoxil | faropenem medoxomil | faropenem sodium | faropenem sodium hydrate | fropenem | sun208 | sun 208 | sun-208 | sun a0026 | sun-a0026

Organizations (9)

Research & Development (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Bacterial Infections ()

Bronchitis, Chronic (Phase 3)

Community-Acquired Infections (Phase 3)

Otitis Media (Phase 2)

Tuberculosis (Phase 1)

Tuberculosis, Pulmonary (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 9

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue